{"ticker": {"uuid": "bd022981-6bf5-4c98-9941-26286708b9db", "symbol": "KRYS", "name": "Krystal Biotech Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Krystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levels", "summary": "Krystal Biotech (KRYS) has seen its institutional ownership surge to a sector-leading score of 10.00, with major investors like ETHSX and BlackRock increasing their holdings by 11.17% quarter-over-quarter. This heightened professional investor interest comes as the company's P/E ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-is-up-72-after-institutional-ownership", "source_name": "Simply Wall Street", "published_at": "2026-06-22T18:40:05", "published_display": "22 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Biotech Firms With Major Potential Catalysts in the Coming Months", "summary": "This article identifies three biotech firms, Vera Therapeutics (VERA), Krystal Biotech (KRYS), and ADMA Biologics (ADMA), that have significant potential catalysts in the near future. Vera and Krystal are clinical-stage companies awaiting key FDA decisions or data readouts for th", "url": "https://www.marketbeat.com/originals/3-biotech-firms-with-major-potential-catalysts-in-the-coming-months/", "source_name": "MarketBeat", "published_at": "2026-06-21T14:10:24", "published_display": "21 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 US Pharmaceutical Stocks With Strong Margins And Earnings Growth", "summary": "This article examines how the US Section 301 investigation into Germany's pharmaceutical pricing could impact American drug companies. It highlights three US pharmaceutical stocks\u2014Krystal Biotech (KRYS), Kiniksa Pharmaceuticals International (KNSA), and Gilead Sciences (GILD)\u2014tha", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/3-us-pharmaceutical-stocks-with-strong-margins-and-earnings/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-19T18:10:52", "published_display": "19 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $403", "summary": "TD Cowen has reiterated its Buy rating for Krystal Biotech (KRYS.US) and increased the price target to $403 from the previous $375. This update reflects the firm's continued confidence in the company's prospects.", "url": "https://www.moomoo.com/news/post/71726687/td-cowen-maintains-krystal-biotech-krysus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-06-19T03:10:52", "published_display": "19 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech (KRYS) Revenue Growth Puts VYJUVEK Pipeline Progress In Focus", "summary": "Krystal Biotech (KRYS) is experiencing significant revenue growth and progress in its rare disease pipeline, particularly with VYJUVEK for dystrophic epidermolysis bullosa. The company's stock has seen substantial gains over the past year, attracting investor attention. While VYJ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-revenue-growth-puts-vyjuvek-pipeline-pr", "source_name": "Simply Wall Street", "published_at": "2026-06-19T00:10:34", "published_display": "19 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech stock hits all-time high at 332.33 USD By Investing.com", "summary": "Krystal Biotech (KRYS) stock reached an all-time high of $332.33, with a market capitalization of $9.74 billion, reflecting a 147.56% increase over the past year. The company's strong performance is supported by a 94% gross profit margin and an \"EXCELLENT\" financial health score.", "url": "https://ng.investing.com/news/company-news/krystal-biotech-stock-hits-alltime-high-at-33233-usd-93CH-2563206", "source_name": "Investing.com Nigeria", "published_at": "2026-06-18T11:10:34", "published_display": "18 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Inc (KRYS) Institutional Confidence", "summary": "Krystal Biotech Inc (KRYS) has an institutional shareholding score of 10.00, placing it first among 388 companies in the Biotechnology & Medical Research industry. Institutional ownership stands at 110.59%, an 11.17% increase quarter-over-quarter. Fidelity Management & Research C", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-krys/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T03:09:12", "published_display": "18 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Inc (KRYS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Krystal Biotech Inc (KRYS), identifying major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-krys/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:56", "published_display": "17 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Inc (KRYS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Krystal Biotech Inc (KRYS) stock, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also presents current stock", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-krys/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:55", "published_display": "17 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Inc (KRYS) Valuation: PE, PB & Fair Value Analysis", "summary": "Krystal Biotech Inc (KRYS) has a current valuation score of 7.41, placing it 241 out of 388 in the Biotechnology & Medical Research industry. Its P/E ratio stands at 44.11, significantly lower than its recent high but above its recent low. The article notes that relevant data for", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-krys/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:12", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Jumps 5.8% Amid Sector-Wide Rally", "summary": "Krystal Biotech (KRYS) saw its shares climb 5.8% to $342.16, participating in a broader rally across the biotechnology sector. The increase was observed alongside similar gains in other biotech companies, suggesting a renewed investor interest in the sector rather than specific c", "url": "https://news.alphastreet.com/krystal-biotech-jumps-5-8-amid-sector-wide-rally/", "source_name": "AlphaStreet", "published_at": "2026-06-17T18:40:17", "published_display": "17 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech stock hits all-time high at 332.33 USD", "summary": "Krystal Biotech Inc.'s stock reached an all-time high of 332.33 USD, reflecting a 147.56% increase over the past year and a market capitalization of $9.74 billion, driven by strong investor confidence and an \"EXCELLENT\" financial health score. The company recently reported exceed", "url": "https://www.investing.com/news/company-news/krystal-biotech-stock-hits-alltime-high-at-33233-usd-93CH-4747600", "source_name": "Investing.com", "published_at": "2026-06-17T09:51:00", "published_display": "17 Jun 2026 09:51", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (KRYS) and Scalable Risk", "summary": "This article analyzes Krystal Biotech Inc. (NASDAQ: KRYS), noting strong sentiment and an exceptional 32.7:1 risk-reward setup, targeting a 9.5% gain versus 0.3% risk. It outlines three AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014tailored for dif", "url": "https://news.stocktradersdaily.com/news_release/101/Understanding_the_Setup:_KRYS_and_Scalable_Risk_061626104002_1781620802.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-16T11:10:00", "published_display": "16 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Inc (KRYS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Krystal Biotech Inc (KRYS) has an earnings forecast score of 8.67, placing it 77th in its industry. Analysts have assigned a consensus \"Buy\" rating with an average target price of $218.00. The company's expected revenue for the next quarter is $125.62M, with anticipated EPS of $1", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-krys/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T09:10:34", "published_display": "16 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech, Inc. (KRYS) Stock Analysis: Evaluating the 31.9% Revenue Growth and Its Implications for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxPMlcyNVFSSG5NMGlxNDNzX0VzNEk4aUdpbFRkT3YyQzM2NlpBeks3QVRNNGc3cmRHOGRnZzRNY244SUt2clBrS1E0UHVvY3BtWTN4UGpCcjlDdWhrMUlJdzFQUTFfb0ZEYXJBR2RIZnRXX1F4REZ3OG9IR1NxVjlsZ0hQMUdCQWFoWDFNcFQ2ODRWakhPdGE1RUh6dlI2QjlTMi1tS1pjUWpKT2pBbzlKRi04cnRqU0FyNHhKTUxNaUJldWdUZEs2VW9LQlBfbExsNlJsX2tKYXVJeUs5SzEwMW1JeHpTTDVnM1NYSWxMazJRUQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T09:24:11+00:00", "published_display": "15 Jun 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks Jump As Trump Touts Iran Deal: SiTime, Krystal Biotech, Howmet In Focus", "summary": "The stock market saw indexes jump on June 11, 2026, following former President Trump's comments about an Iran deal. This report highlights the day's market action with Alissa Coram and Ken Shreve discussing key stocks such as SiTime, Krystal Biotech, and Howmet Aerospace. The art", "url": "https://investors.com/videos/stock-market-today-indexes-jump-trump-iran-deal-sitm-krys-hwm/", "source_name": "Investor's Business Daily", "published_at": "2026-06-11T16:47:00", "published_display": "11 Jun 2026 16:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech stock hits all-time high at 319.6 USD", "summary": "Krystal Biotech (KRYS) stock reached an all-time high of $319.60, currently trading at $318.08 with a market capitalization of $9.37 billion. The company has seen a 124% increase in its stock price over the past year, driven by strong gross profit margins of 94% and a healthy bal", "url": "https://in.investing.com/news/company-news/krystal-biotech-stock-hits-alltime-high-at-3196-usd-93CH-5448810", "source_name": "Investing.com India", "published_at": "2026-06-10T17:40:42", "published_display": "10 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KRYS: Future Returns Will Reflect UK Approval And Mixed Execution Debate", "summary": "Krystal Biotech's analyst price targets have seen modest adjustments, reflecting both optimism and caution among analysts. Bullish reports highlight confidence in current valuations and execution, while bearish views concern over-optimistic valuations and execution risks. The com", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/1gwwo8tx-krys-global-expansion-and-pipeline-shifts-will-shape-near-term-performance/updates/20-krystal-biotechs-analyst-price-target-has-shifted-modestly", "source_name": "Simply Wall Street", "published_at": "2026-06-10T06:10:25", "published_display": "10 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash per share of Krystal Biotech, Inc. \u2013 MUN:4KB", "summary": "This article provides financial information for Krystal Biotech, Inc. (MUN:4KB), specifically focusing on its cash per share. The content appears to be a stub or a section within a larger financial data platform, indicating where to find financial metrics for the company on the M", "url": "https://www.tradingview.com/symbols/MUN-4KB/financials-statistics-and-ratios/cash-per-share/", "source_name": "TradingView", "published_at": "2026-06-10T00:10:52", "published_display": "10 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Insider Has Just Sold Shares In Krystal Biotech", "summary": "Krystal Biotech's founder, Krish Krishnan, recently sold US$7.6m worth of stock, reducing their holding by 1.7%. This was the largest insider sale in the past year, occurring at a price close to the current share price. While the sale raises some caution, the company remains prof", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/this-insider-has-just-sold-shares-in-krystal-biotech", "source_name": "Simply Wall Street", "published_at": "2026-06-09T11:09:50", "published_display": "09 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings and a Promising 7.24% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQdHJCd0JqM2xlNklmdk95ckVGZXhQc1Z0OG5ydXdYdE53c0ZkbGtZT0J1QkNPc0RmTTF2b2hyMFFVczdYWlFKU2R0OGo4UTlFR3JVMnpWOURoVzdkLUJHWmhROXc2b1k2SkVadWcwd1pCdHpIamRUYmhnaHdjMEE3VC14SHVPNDlmalM0a2UyN2NaSlNUdDg2UndCOGtvX0Q2U1Q5TkQxNl9MbEttbW1tS19IU0w0dmJwWGR0c2JhNy03bWpxZl8ydElmYmNfSTlWRGY4eWFHelVNYmF2SHFKYQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Insider Sold Shares Worth $7,702,984, According to a Recent SEC Filing", "summary": "An insider at Krystal Biotech (NASDAQ: KRYS) has sold shares valued at $7,702,984, as detailed in a recent SEC filing. The company is a commercial-stage biotechnology firm focused on developing genetic medicines for diseases with high unmet needs, including its approved product V", "url": "https://www.marketscreener.com/news/krystal-biotech-insider-sold-shares-worth-7-702-984-according-to-a-recent-sec-filing-ce7f5dd2de8bfe27", "source_name": "www.marketscreener.com", "published_at": "2026-06-08T07:40:04", "published_display": "08 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now?", "summary": "Krystal Biotech (KRYS) is presented as a strong investment due to its gene therapy platform for rare diseases, highlighted by its commercialized product VYJUVEK and a robust pipeline across multiple indications. The article emphasizes the potential for significant growth, recurri", "url": "https://ca.finance.yahoo.com/news/krystal-biotech-inc-krys-good-171815552.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-07T17:18:00", "published_display": "07 Jun 2026 17:18", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech, Inc. Balance Sheet \u2013 XETR:4KB", "summary": "Krystal Biotech, Inc.'s balance sheet for Q1 2026 shows total assets of 1.21 billion EUR, a 6.47% increase from Q4 2025. Total liabilities also rose by 7.00% to 104.07 million EUR in the first quarter of 2026. This article provides a snapshot of the company's financial position a", "url": "https://www.tradingview.com/symbols/XETR-4KB/financials-balance-sheet/", "source_name": "TradingView", "published_at": "2026-06-06T18:09:33", "published_display": "06 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech, Inc. Cash Flow \u2013 XETR:4KB", "summary": "This article provides key cash flow metrics for Krystal Biotech, Inc. (XETR:4KB). It highlights that the free cash flow for Q1 2026 was \u20ac63.39 million, while for 2025, it stood at \u20ac160.84 million with an operating cash flow of \u20ac171.02 million. The data is presented in EUR and inc", "url": "https://www.tradingview.com/symbols/XETR-4KB/financials-cash-flow/", "source_name": "TradingView", "published_at": "2026-06-06T18:09:33", "published_display": "06 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Strong Vyjuvek Earnings And Analyst Optimism Require Action From Krystal Biotech (KRYS) Investors?", "summary": "Krystal Biotech reported strong first-quarter 2026 results, exceeding earnings expectations due to robust Vyjuvek sales and patient uptake, which analysts view positively. The article explores how this performance shapes the company's investment narrative, emphasizing growth, con", "url": "https://www.sahmcapital.com/news/content/should-strong-vyjuvek-earnings-and-analyst-optimism-require-action-from-krystal-biotech-krys-investors-2026-06-06", "source_name": "Sahm", "published_at": "2026-06-06T16:40:04", "published_display": "06 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech CEO Krishnan sells $7.7m in company stock", "summary": "Krystal Biotech CEO Krishnan sold approximately $7.7 million worth of company stock through a pre-arranged trading plan. This sale involved 25,000 shares, occurring while the company's stock trades near its 52-week high after a 127% return over the past year. Despite the sale, In", "url": "https://www.investing.com/news/insider-trading-news/krystal-biotech-ceo-krishnan-sells-77m-in-company-stock-93CH-4729397", "source_name": "Investing.com", "published_at": "2026-06-06T16:40:04", "published_display": "06 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech (KRYS) CEO trades 25,000 shares under 10b5-1 plan", "summary": "Krystal Biotech's President and CEO, Krish S. Krishnan, sold 25,000 shares of common stock on June 4, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. The sales were executed in multiple trades at weighted average prices between $300.75 and $312.23 p", "url": "https://www.stocktitan.net/sec-filings/KRYS/form-4-krystal-biotech-inc-insider-trading-activity-c41ea3521ce6.html", "source_name": "Stock Titan", "published_at": "2026-06-06T16:10:58", "published_display": "06 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "25K-share sale by Krystal Biotech (NASDAQ: KRYS) R&D head", "summary": "Krystal Biotech's President of R&D, Suma Krishnan, sold 25,000 shares of common stock on June 4, 2026, through multiple open-market transactions. These sales, valued at approximately $7.7 million, were conducted under a pre-established Rule 10b5-1 trading plan. Krishnan also main", "url": "https://www.stocktitan.net/sec-filings/KRYS/form-4-krystal-biotech-inc-insider-trading-activity-5ff709eae45d.html", "source_name": "Stock Titan", "published_at": "2026-06-06T04:09:33", "published_display": "06 Jun 2026 04:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is the Options Market Predicting a Spike in Krystal Biotech Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMmZBeTlpQ2NXaDJMWDltN0dMcVF2NzJjc1JyZGI2RUc4NXZHcGM2Wk9hMGtKSnB6QlBaSS1xeWZ6VUxBRV91UHVZUVByYUwwaHN5ZkdVNjg2S25wWXRWOUpoMHZ6OEdWLW14cHRrbi14b1Bzc1J2U1daU3hMNVVvcXN6RXFYbDNUQ29SRU1vMVBLZThITzlJNWpnandENWdTdU9lMjc0ZXppQQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Krystal Biotech (KRYS) Valuation After Vyjuvek Driven Earnings Beat And Pipeline Progress", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOaC1wV0wwNGw4SVA3STE0SEZKbXVuXzl5RE5IeTgwV3dXdy1lMEZKbVVkREI3a1VYR3MyQk05bDY5T0tkblJEYVd1ZE8wZTd6Tmd5dXFKeFh2cm03V01wM0x0UDY3blRMOXp5bld1YUVBcWI5dUd3OFk5UHJ4Y25DejZtb29PdmRHc2ZuQ25XTWZORjY5dlE?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech receives UK approval for gene therapy VYJUVEK By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOc3UwUFhERi03MTQ0bDFrbDM1cTk3SFpQNmprbV9ldGFneVVMelRaSVR6TzBoa2U1M2tkN2ZsaFhJeF96XzJ1bThQQS05aU5hU1FNSWc2SWFxZXlxUEpaSUMtNFVwVXEyMlpWOGZFaEk5SlBxbC1OVlVFemRIRGljTEpqbWQyQm5ZLW9YY1hxbkxpUldPbzJFVVVTNk5ockd1S3VOanRqTTk3SC1GNWRTeHNzR0o4bEVTSXp6RTVXVQ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Underlying Issues With The Quality Of Krystal Biotech's (NASDAQ:KRYS) Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNVElVUGVIYUIxWDh3ZlNEX2k2cVlXb1lTRS1jSlVFSEo2anNJdWpkLV8wUE4xWm4tMnFWbnNjZDVuMTdZd042am9tQ0Y4MjQ0Q3lqZUZkaFBQdzExU3FLM2hJYmRjSWgtbUt2NzRkSXlVdnc1LWxWckdyMEhTY0g2WEJpV3hMYnVCMmh3aThTRDZyWmZhUlgzNUxLZEtXRnR2QzVDa2hUeVhvUkpiczR4clM4MTBuUlF2aXlYZnJ4SFpKeUJUY1RrQ1VUdWJtdkE5RXc?oc=5", "source_name": "ChartMill", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Krystal Biotech (KRYS) After Its Strong Share Price Run?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech CEO to speak May 13 at BofA health care event", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOUUZRVThOZjFJZ2t4OC11ZkNDRlpUemRYRHdFRG9HWWJEUm1QZzRMd1VLeEx1RU1Xa3Z1NHluSk53NDBPRHlxZF9ZX19XcEtrc1N1R0NVOWpMUXUxOTY5WGpaZlRBWG1TOTZNcUdvQkswM0lnUGJQallYZF8zbTM5NkY4SzFzempKWjYwdThNdWpaMnV6bHBWeFZJVjYwRkU2Y3YyMHNmNEc0RkRVbkNTNUw4TjRQYkJmS3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQZmE0Y1hFbzlfT0dnQjRfenVMN1BOWTBkT1UzLVNWZzdUcE9rb0tjWk5ERXBFTks5YXhFOHdCcFZ4TVJnaElOQl9VM3lRTTVpbTVwYTFrTHF0d0wycWZRaHlMT0NkSTZra3k1dFVpT2VRM3NpT1M5MEdmLU84cDZULVdDTnRjb2xvMWp5MEE3V1F2cXpWR2Ixb2ZNSjV1dC1FbUgwNg?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Krystal Biotech (KRYS) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPZUxKRkZQZ0tGMmQzMlBNUkRIcENhWU5aN0tDX3pvZTdDa3gwTGllQnN4THV0M2hsWndsZ0NmM0I1bE5oS1lmTG8teHpZNjAyeUs3TTVEMTlzeWhINXhSLW44MTUxckYxYmx3bV9fa2tCNUtzZ2NrVm9FYlFaR3ctRkNfbkpyOEJZTGljYnZJay1CVWloUk54TklmUm82NFJsWGc?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech reports $116.4M in sales as key eye study fills", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOekF0V2JBZVVENGZraWUwRnBTaldSODBiMEVMcHBRZnc0bFE1VUxaN085cXdEMno4TFBBb2tYUzVCZ3RhTlduUFp6am9VZ21GNktsNGNBVEJJWXczMzRIMVc5am1ZS0x6U3NESjM3VGozVDdHVUNpZkRLZEFybGFYNDI4ZDhLaG9FR0FSTGFOT2RZQThBSU5SN0hYTnhRZzJVbzI4QjZHYktONWdNNDhFcF9QajRFdEhrN0dxQy1vS24?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQREx2dUhhRGhTdVlIX0RkM0JpbExqcnJRVnFUQ3YyOEhSTFdlNG9NZW5rOUxVLXkyejRJMm9VdTdQZGRsbVFvekpnWDNwd0oyVkdHb05TSTlHNG5PSW1xaEhWS3FyRlFOMVZEcWhnX0dWQlJMRDJXcWxWLU5XM3F2Um5RTjBmZzNDTHMzR3BOb0hheXEza1cxY0xB?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPX0RsOUk2anBtc0xRaUtrZC1PdHpwa0U1WjBiXzVXMzhDLThrUGplT3VLeFVYb1VYWGYxeDFtOTY5NFpibGUzaGR2S3NSanBHR05PZGszZllIOGJxNDgxSE5Qb2taSVlNQnhtNU5hcXVmTW9tNHlWLTdweXA2QmVjUXU1WmNtNE1wSFgzSmFIOThaSjgzWmZIVVd5RWRGWFU?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vyjuvek Label Update And KB803 Progress Reshape Krystal Biotech Story", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Krystal Biotech (KRYS) After Strong Multi\u2011Year Share Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNTUlwN1VmVlc5b2FlU3E5Nm5FejNoQ2pTV0FXZjNneDBtYjRsWjlLb0l5bllaNzhZN0J5YnhFTl9QNUpndWhpdTRYdE1qclpDeEY1cTZDYk9kZGtBWThYTVhsSjVfUEdYMkY3WDYxRHNoREV6ZC1ZeF9wZHdPZmJjUmVCWUJDZw?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQR2hONl95bVVUb2FsbTBZLTRrV2wyazFfVGdERkdyaVZtUlFIV25ONTA1dmNfaWpfeUJYWGEwT3lhNGNNdV9KVGFlS19vaDdTQ0gyckVoZlN2RUFBdUhNODVCUk11c2VKbXp1VEozSUpEdEJqaFJZYnlORVVFRms4UUxkbU9jTnBKN3o4?oc=5", "source_name": "Market source", "published_at": "2026-02-21T08:00:00+00:00", "published_display": "21 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOMFkyMDNQWVFJZkZ5b0JJaUVQb2ZZdlIyMDJ1dFdhb3BkTVZLNk5JT3VKQlJUb2hpM2Z2cDRHczR6c2IxenR6TExOaEMzVjBVNzhEdFlyNC1ReDR4d3F2MnFObjdyMWRULWJRM090Y3lPOEZIWllrS05rX0xSNUdIdUV1MXNKSTVvcmhhQ05aSUxXc04tRlpv?oc=5", "source_name": "Finviz", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyjuvek Growth Powers Krystal Biotech\u2019s (KRYS) Huge Upward Analyst Target Price Revision", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOSUtGcjdINUNxX25sM0dzS25ob21rdk9RblltRFp2OWk3NUJYYW54X3plaVFleDB6SUZNY2lobGF1TG8zM25XdHNzZTBoZVF5ck5oRTJBTnJJZ1JyaDFMNWN4SE1OVDhKVzBIazFQZWd2SUlwRWxTWUh0S0VNaTR5WkU5cDkyME9FUVZZ?oc=5", "source_name": "Market source", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Market Participants Recognise Krystal Biotech, Inc.'s (NASDAQ:KRYS) Earnings Pushing Shares 29% Higher", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Krystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levels", "summary": "Krystal Biotech (KRYS) has seen its institutional ownership surge to a sector-leading score of 10.00, with major investors like ETHSX and BlackRock increasing their holdings by 11.17% quarter-over-quarter. This heightened professional investor interest comes as the company's P/E ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-is-up-72-after-institutional-ownership", "source_name": "Simply Wall Street", "published_at": "2026-06-22T18:40:05", "published_display": "22 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Biotech Firms With Major Potential Catalysts in the Coming Months", "summary": "This article identifies three biotech firms, Vera Therapeutics (VERA), Krystal Biotech (KRYS), and ADMA Biologics (ADMA), that have significant potential catalysts in the near future. Vera and Krystal are clinical-stage companies awaiting key FDA decisions or data readouts for th", "url": "https://www.marketbeat.com/originals/3-biotech-firms-with-major-potential-catalysts-in-the-coming-months/", "source_name": "MarketBeat", "published_at": "2026-06-21T14:10:24", "published_display": "21 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 US Pharmaceutical Stocks With Strong Margins And Earnings Growth", "summary": "This article examines how the US Section 301 investigation into Germany's pharmaceutical pricing could impact American drug companies. It highlights three US pharmaceutical stocks\u2014Krystal Biotech (KRYS), Kiniksa Pharmaceuticals International (KNSA), and Gilead Sciences (GILD)\u2014tha", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/3-us-pharmaceutical-stocks-with-strong-margins-and-earnings/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-19T18:10:52", "published_display": "19 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $403", "summary": "TD Cowen has reiterated its Buy rating for Krystal Biotech (KRYS.US) and increased the price target to $403 from the previous $375. This update reflects the firm's continued confidence in the company's prospects.", "url": "https://www.moomoo.com/news/post/71726687/td-cowen-maintains-krystal-biotech-krysus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-06-19T03:10:52", "published_display": "19 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech (KRYS) Revenue Growth Puts VYJUVEK Pipeline Progress In Focus", "summary": "Krystal Biotech (KRYS) is experiencing significant revenue growth and progress in its rare disease pipeline, particularly with VYJUVEK for dystrophic epidermolysis bullosa. The company's stock has seen substantial gains over the past year, attracting investor attention. While VYJ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-revenue-growth-puts-vyjuvek-pipeline-pr", "source_name": "Simply Wall Street", "published_at": "2026-06-19T00:10:34", "published_display": "19 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech stock hits all-time high at 332.33 USD By Investing.com", "summary": "Krystal Biotech (KRYS) stock reached an all-time high of $332.33, with a market capitalization of $9.74 billion, reflecting a 147.56% increase over the past year. The company's strong performance is supported by a 94% gross profit margin and an \"EXCELLENT\" financial health score.", "url": "https://ng.investing.com/news/company-news/krystal-biotech-stock-hits-alltime-high-at-33233-usd-93CH-2563206", "source_name": "Investing.com Nigeria", "published_at": "2026-06-18T11:10:34", "published_display": "18 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Inc (KRYS) Institutional Confidence", "summary": "Krystal Biotech Inc (KRYS) has an institutional shareholding score of 10.00, placing it first among 388 companies in the Biotechnology & Medical Research industry. Institutional ownership stands at 110.59%, an 11.17% increase quarter-over-quarter. Fidelity Management & Research C", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-krys/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T03:09:12", "published_display": "18 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Inc (KRYS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Krystal Biotech Inc (KRYS), identifying major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-krys/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:56", "published_display": "17 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Inc (KRYS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Krystal Biotech Inc (KRYS) stock, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also presents current stock", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-krys/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:55", "published_display": "17 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Inc (KRYS) Valuation: PE, PB & Fair Value Analysis", "summary": "Krystal Biotech Inc (KRYS) has a current valuation score of 7.41, placing it 241 out of 388 in the Biotechnology & Medical Research industry. Its P/E ratio stands at 44.11, significantly lower than its recent high but above its recent low. The article notes that relevant data for", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-krys/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:12", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Jumps 5.8% Amid Sector-Wide Rally", "summary": "Krystal Biotech (KRYS) saw its shares climb 5.8% to $342.16, participating in a broader rally across the biotechnology sector. The increase was observed alongside similar gains in other biotech companies, suggesting a renewed investor interest in the sector rather than specific c", "url": "https://news.alphastreet.com/krystal-biotech-jumps-5-8-amid-sector-wide-rally/", "source_name": "AlphaStreet", "published_at": "2026-06-17T18:40:17", "published_display": "17 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech stock hits all-time high at 332.33 USD", "summary": "Krystal Biotech Inc.'s stock reached an all-time high of 332.33 USD, reflecting a 147.56% increase over the past year and a market capitalization of $9.74 billion, driven by strong investor confidence and an \"EXCELLENT\" financial health score. The company recently reported exceed", "url": "https://www.investing.com/news/company-news/krystal-biotech-stock-hits-alltime-high-at-33233-usd-93CH-4747600", "source_name": "Investing.com", "published_at": "2026-06-17T09:51:00", "published_display": "17 Jun 2026 09:51", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (KRYS) and Scalable Risk", "summary": "This article analyzes Krystal Biotech Inc. (NASDAQ: KRYS), noting strong sentiment and an exceptional 32.7:1 risk-reward setup, targeting a 9.5% gain versus 0.3% risk. It outlines three AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014tailored for dif", "url": "https://news.stocktradersdaily.com/news_release/101/Understanding_the_Setup:_KRYS_and_Scalable_Risk_061626104002_1781620802.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-16T11:10:00", "published_display": "16 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Inc (KRYS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Krystal Biotech Inc (KRYS) has an earnings forecast score of 8.67, placing it 77th in its industry. Analysts have assigned a consensus \"Buy\" rating with an average target price of $218.00. The company's expected revenue for the next quarter is $125.62M, with anticipated EPS of $1", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-krys/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T09:10:34", "published_display": "16 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech, Inc. (KRYS) Stock Analysis: Evaluating the 31.9% Revenue Growth and Its Implications for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxPMlcyNVFSSG5NMGlxNDNzX0VzNEk4aUdpbFRkT3YyQzM2NlpBeks3QVRNNGc3cmRHOGRnZzRNY244SUt2clBrS1E0UHVvY3BtWTN4UGpCcjlDdWhrMUlJdzFQUTFfb0ZEYXJBR2RIZnRXX1F4REZ3OG9IR1NxVjlsZ0hQMUdCQWFoWDFNcFQ2ODRWakhPdGE1RUh6dlI2QjlTMi1tS1pjUWpKT2pBbzlKRi04cnRqU0FyNHhKTUxNaUJldWdUZEs2VW9LQlBfbExsNlJsX2tKYXVJeUs5SzEwMW1JeHpTTDVnM1NYSWxMazJRUQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T09:24:11+00:00", "published_display": "15 Jun 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks Jump As Trump Touts Iran Deal: SiTime, Krystal Biotech, Howmet In Focus", "summary": "The stock market saw indexes jump on June 11, 2026, following former President Trump's comments about an Iran deal. This report highlights the day's market action with Alissa Coram and Ken Shreve discussing key stocks such as SiTime, Krystal Biotech, and Howmet Aerospace. The art", "url": "https://investors.com/videos/stock-market-today-indexes-jump-trump-iran-deal-sitm-krys-hwm/", "source_name": "Investor's Business Daily", "published_at": "2026-06-11T16:47:00", "published_display": "11 Jun 2026 16:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech stock hits all-time high at 319.6 USD", "summary": "Krystal Biotech (KRYS) stock reached an all-time high of $319.60, currently trading at $318.08 with a market capitalization of $9.37 billion. The company has seen a 124% increase in its stock price over the past year, driven by strong gross profit margins of 94% and a healthy bal", "url": "https://in.investing.com/news/company-news/krystal-biotech-stock-hits-alltime-high-at-3196-usd-93CH-5448810", "source_name": "Investing.com India", "published_at": "2026-06-10T17:40:42", "published_display": "10 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KRYS: Future Returns Will Reflect UK Approval And Mixed Execution Debate", "summary": "Krystal Biotech's analyst price targets have seen modest adjustments, reflecting both optimism and caution among analysts. Bullish reports highlight confidence in current valuations and execution, while bearish views concern over-optimistic valuations and execution risks. The com", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/1gwwo8tx-krys-global-expansion-and-pipeline-shifts-will-shape-near-term-performance/updates/20-krystal-biotechs-analyst-price-target-has-shifted-modestly", "source_name": "Simply Wall Street", "published_at": "2026-06-10T06:10:25", "published_display": "10 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash per share of Krystal Biotech, Inc. \u2013 MUN:4KB", "summary": "This article provides financial information for Krystal Biotech, Inc. (MUN:4KB), specifically focusing on its cash per share. The content appears to be a stub or a section within a larger financial data platform, indicating where to find financial metrics for the company on the M", "url": "https://www.tradingview.com/symbols/MUN-4KB/financials-statistics-and-ratios/cash-per-share/", "source_name": "TradingView", "published_at": "2026-06-10T00:10:52", "published_display": "10 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Insider Has Just Sold Shares In Krystal Biotech", "summary": "Krystal Biotech's founder, Krish Krishnan, recently sold US$7.6m worth of stock, reducing their holding by 1.7%. This was the largest insider sale in the past year, occurring at a price close to the current share price. While the sale raises some caution, the company remains prof", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/this-insider-has-just-sold-shares-in-krystal-biotech", "source_name": "Simply Wall Street", "published_at": "2026-06-09T11:09:50", "published_display": "09 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings and a Promising 7.24% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQdHJCd0JqM2xlNklmdk95ckVGZXhQc1Z0OG5ydXdYdE53c0ZkbGtZT0J1QkNPc0RmTTF2b2hyMFFVczdYWlFKU2R0OGo4UTlFR3JVMnpWOURoVzdkLUJHWmhROXc2b1k2SkVadWcwd1pCdHpIamRUYmhnaHdjMEE3VC14SHVPNDlmalM0a2UyN2NaSlNUdDg2UndCOGtvX0Q2U1Q5TkQxNl9MbEttbW1tS19IU0w0dmJwWGR0c2JhNy03bWpxZl8ydElmYmNfSTlWRGY4eWFHelVNYmF2SHFKYQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Insider Sold Shares Worth $7,702,984, According to a Recent SEC Filing", "summary": "An insider at Krystal Biotech (NASDAQ: KRYS) has sold shares valued at $7,702,984, as detailed in a recent SEC filing. The company is a commercial-stage biotechnology firm focused on developing genetic medicines for diseases with high unmet needs, including its approved product V", "url": "https://www.marketscreener.com/news/krystal-biotech-insider-sold-shares-worth-7-702-984-according-to-a-recent-sec-filing-ce7f5dd2de8bfe27", "source_name": "www.marketscreener.com", "published_at": "2026-06-08T07:40:04", "published_display": "08 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now?", "summary": "Krystal Biotech (KRYS) is presented as a strong investment due to its gene therapy platform for rare diseases, highlighted by its commercialized product VYJUVEK and a robust pipeline across multiple indications. The article emphasizes the potential for significant growth, recurri", "url": "https://ca.finance.yahoo.com/news/krystal-biotech-inc-krys-good-171815552.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-07T17:18:00", "published_display": "07 Jun 2026 17:18", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech, Inc. Balance Sheet \u2013 XETR:4KB", "summary": "Krystal Biotech, Inc.'s balance sheet for Q1 2026 shows total assets of 1.21 billion EUR, a 6.47% increase from Q4 2025. Total liabilities also rose by 7.00% to 104.07 million EUR in the first quarter of 2026. This article provides a snapshot of the company's financial position a", "url": "https://www.tradingview.com/symbols/XETR-4KB/financials-balance-sheet/", "source_name": "TradingView", "published_at": "2026-06-06T18:09:33", "published_display": "06 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech, Inc. Cash Flow \u2013 XETR:4KB", "summary": "This article provides key cash flow metrics for Krystal Biotech, Inc. (XETR:4KB). It highlights that the free cash flow for Q1 2026 was \u20ac63.39 million, while for 2025, it stood at \u20ac160.84 million with an operating cash flow of \u20ac171.02 million. The data is presented in EUR and inc", "url": "https://www.tradingview.com/symbols/XETR-4KB/financials-cash-flow/", "source_name": "TradingView", "published_at": "2026-06-06T18:09:33", "published_display": "06 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Strong Vyjuvek Earnings And Analyst Optimism Require Action From Krystal Biotech (KRYS) Investors?", "summary": "Krystal Biotech reported strong first-quarter 2026 results, exceeding earnings expectations due to robust Vyjuvek sales and patient uptake, which analysts view positively. The article explores how this performance shapes the company's investment narrative, emphasizing growth, con", "url": "https://www.sahmcapital.com/news/content/should-strong-vyjuvek-earnings-and-analyst-optimism-require-action-from-krystal-biotech-krys-investors-2026-06-06", "source_name": "Sahm", "published_at": "2026-06-06T16:40:04", "published_display": "06 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech CEO Krishnan sells $7.7m in company stock", "summary": "Krystal Biotech CEO Krishnan sold approximately $7.7 million worth of company stock through a pre-arranged trading plan. This sale involved 25,000 shares, occurring while the company's stock trades near its 52-week high after a 127% return over the past year. Despite the sale, In", "url": "https://www.investing.com/news/insider-trading-news/krystal-biotech-ceo-krishnan-sells-77m-in-company-stock-93CH-4729397", "source_name": "Investing.com", "published_at": "2026-06-06T16:40:04", "published_display": "06 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech (KRYS) CEO trades 25,000 shares under 10b5-1 plan", "summary": "Krystal Biotech's President and CEO, Krish S. Krishnan, sold 25,000 shares of common stock on June 4, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. The sales were executed in multiple trades at weighted average prices between $300.75 and $312.23 p", "url": "https://www.stocktitan.net/sec-filings/KRYS/form-4-krystal-biotech-inc-insider-trading-activity-c41ea3521ce6.html", "source_name": "Stock Titan", "published_at": "2026-06-06T16:10:58", "published_display": "06 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "25K-share sale by Krystal Biotech (NASDAQ: KRYS) R&D head", "summary": "Krystal Biotech's President of R&D, Suma Krishnan, sold 25,000 shares of common stock on June 4, 2026, through multiple open-market transactions. These sales, valued at approximately $7.7 million, were conducted under a pre-established Rule 10b5-1 trading plan. Krishnan also main", "url": "https://www.stocktitan.net/sec-filings/KRYS/form-4-krystal-biotech-inc-insider-trading-activity-5ff709eae45d.html", "source_name": "Stock Titan", "published_at": "2026-06-06T04:09:33", "published_display": "06 Jun 2026 04:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is the Options Market Predicting a Spike in Krystal Biotech Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMmZBeTlpQ2NXaDJMWDltN0dMcVF2NzJjc1JyZGI2RUc4NXZHcGM2Wk9hMGtKSnB6QlBaSS1xeWZ6VUxBRV91UHVZUVByYUwwaHN5ZkdVNjg2S25wWXRWOUpoMHZ6OEdWLW14cHRrbi14b1Bzc1J2U1daU3hMNVVvcXN6RXFYbDNUQ29SRU1vMVBLZThITzlJNWpnandENWdTdU9lMjc0ZXppQQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Krystal Biotech (KRYS) Valuation After Vyjuvek Driven Earnings Beat And Pipeline Progress", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOaC1wV0wwNGw4SVA3STE0SEZKbXVuXzl5RE5IeTgwV3dXdy1lMEZKbVVkREI3a1VYR3MyQk05bDY5T0tkblJEYVd1ZE8wZTd6Tmd5dXFKeFh2cm03V01wM0x0UDY3blRMOXp5bld1YUVBcWI5dUd3OFk5UHJ4Y25DejZtb29PdmRHc2ZuQ25XTWZORjY5dlE?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech receives UK approval for gene therapy VYJUVEK By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOc3UwUFhERi03MTQ0bDFrbDM1cTk3SFpQNmprbV9ldGFneVVMelRaSVR6TzBoa2U1M2tkN2ZsaFhJeF96XzJ1bThQQS05aU5hU1FNSWc2SWFxZXlxUEpaSUMtNFVwVXEyMlpWOGZFaEk5SlBxbC1OVlVFemRIRGljTEpqbWQyQm5ZLW9YY1hxbkxpUldPbzJFVVVTNk5ockd1S3VOanRqTTk3SC1GNWRTeHNzR0o4bEVTSXp6RTVXVQ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Underlying Issues With The Quality Of Krystal Biotech's (NASDAQ:KRYS) Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNVElVUGVIYUIxWDh3ZlNEX2k2cVlXb1lTRS1jSlVFSEo2anNJdWpkLV8wUE4xWm4tMnFWbnNjZDVuMTdZd042am9tQ0Y4MjQ0Q3lqZUZkaFBQdzExU3FLM2hJYmRjSWgtbUt2NzRkSXlVdnc1LWxWckdyMEhTY0g2WEJpV3hMYnVCMmh3aThTRDZyWmZhUlgzNUxLZEtXRnR2QzVDa2hUeVhvUkpiczR4clM4MTBuUlF2aXlYZnJ4SFpKeUJUY1RrQ1VUdWJtdkE5RXc?oc=5", "source_name": "ChartMill", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Krystal Biotech (KRYS) After Its Strong Share Price Run?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech CEO to speak May 13 at BofA health care event", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOUUZRVThOZjFJZ2t4OC11ZkNDRlpUemRYRHdFRG9HWWJEUm1QZzRMd1VLeEx1RU1Xa3Z1NHluSk53NDBPRHlxZF9ZX19XcEtrc1N1R0NVOWpMUXUxOTY5WGpaZlRBWG1TOTZNcUdvQkswM0lnUGJQallYZF8zbTM5NkY4SzFzempKWjYwdThNdWpaMnV6bHBWeFZJVjYwRkU2Y3YyMHNmNEc0RkRVbkNTNUw4TjRQYkJmS3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQZmE0Y1hFbzlfT0dnQjRfenVMN1BOWTBkT1UzLVNWZzdUcE9rb0tjWk5ERXBFTks5YXhFOHdCcFZ4TVJnaElOQl9VM3lRTTVpbTVwYTFrTHF0d0wycWZRaHlMT0NkSTZra3k1dFVpT2VRM3NpT1M5MEdmLU84cDZULVdDTnRjb2xvMWp5MEE3V1F2cXpWR2Ixb2ZNSjV1dC1FbUgwNg?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Krystal Biotech (KRYS) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPZUxKRkZQZ0tGMmQzMlBNUkRIcENhWU5aN0tDX3pvZTdDa3gwTGllQnN4THV0M2hsWndsZ0NmM0I1bE5oS1lmTG8teHpZNjAyeUs3TTVEMTlzeWhINXhSLW44MTUxckYxYmx3bV9fa2tCNUtzZ2NrVm9FYlFaR3ctRkNfbkpyOEJZTGljYnZJay1CVWloUk54TklmUm82NFJsWGc?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech reports $116.4M in sales as key eye study fills", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOekF0V2JBZVVENGZraWUwRnBTaldSODBiMEVMcHBRZnc0bFE1VUxaN085cXdEMno4TFBBb2tYUzVCZ3RhTlduUFp6am9VZ21GNktsNGNBVEJJWXczMzRIMVc5am1ZS0x6U3NESjM3VGozVDdHVUNpZkRLZEFybGFYNDI4ZDhLaG9FR0FSTGFOT2RZQThBSU5SN0hYTnhRZzJVbzI4QjZHYktONWdNNDhFcF9QajRFdEhrN0dxQy1vS24?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQREx2dUhhRGhTdVlIX0RkM0JpbExqcnJRVnFUQ3YyOEhSTFdlNG9NZW5rOUxVLXkyejRJMm9VdTdQZGRsbVFvekpnWDNwd0oyVkdHb05TSTlHNG5PSW1xaEhWS3FyRlFOMVZEcWhnX0dWQlJMRDJXcWxWLU5XM3F2Um5RTjBmZzNDTHMzR3BOb0hheXEza1cxY0xB?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPX0RsOUk2anBtc0xRaUtrZC1PdHpwa0U1WjBiXzVXMzhDLThrUGplT3VLeFVYb1VYWGYxeDFtOTY5NFpibGUzaGR2S3NSanBHR05PZGszZllIOGJxNDgxSE5Qb2taSVlNQnhtNU5hcXVmTW9tNHlWLTdweXA2QmVjUXU1WmNtNE1wSFgzSmFIOThaSjgzWmZIVVd5RWRGWFU?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyjuvek Label Update And KB803 Progress Reshape Krystal Biotech Story", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Krystal Biotech (KRYS) After Strong Multi\u2011Year Share Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNTUlwN1VmVlc5b2FlU3E5Nm5FejNoQ2pTV0FXZjNneDBtYjRsWjlLb0l5bllaNzhZN0J5YnhFTl9QNUpndWhpdTRYdE1qclpDeEY1cTZDYk9kZGtBWThYTVhsSjVfUEdYMkY3WDYxRHNoREV6ZC1ZeF9wZHdPZmJjUmVCWUJDZw?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQR2hONl95bVVUb2FsbTBZLTRrV2wyazFfVGdERkdyaVZtUlFIV25ONTA1dmNfaWpfeUJYWGEwT3lhNGNNdV9KVGFlS19vaDdTQ0gyckVoZlN2RUFBdUhNODVCUk11c2VKbXp1VEozSUpEdEJqaFJZYnlORVVFRms4UUxkbU9jTnBKN3o4?oc=5", "source_name": "Market source", "published_at": "2026-02-21T08:00:00+00:00", "published_display": "21 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOMFkyMDNQWVFJZkZ5b0JJaUVQb2ZZdlIyMDJ1dFdhb3BkTVZLNk5JT3VKQlJUb2hpM2Z2cDRHczR6c2IxenR6TExOaEMzVjBVNzhEdFlyNC1ReDR4d3F2MnFObjdyMWRULWJRM090Y3lPOEZIWllrS05rX0xSNUdIdUV1MXNKSTVvcmhhQ05aSUxXc04tRlpv?oc=5", "source_name": "Finviz", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyjuvek Growth Powers Krystal Biotech\u2019s (KRYS) Huge Upward Analyst Target Price Revision", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOSUtGcjdINUNxX25sM0dzS25ob21rdk9RblltRFp2OWk3NUJYYW54X3plaVFleDB6SUZNY2lobGF1TG8zM25XdHNzZTBoZVF5ck5oRTJBTnJJZ1JyaDFMNWN4SE1OVDhKVzBIazFQZWd2SUlwRWxTWUh0S0VNaTR5WkU5cDkyME9FUVZZ?oc=5", "source_name": "Market source", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Market Participants Recognise Krystal Biotech, Inc.'s (NASDAQ:KRYS) Earnings Pushing Shares 29% Higher", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 56, "sentiment_summary": {"positive": 25, "negative": 5, "neutral": 26, "score": 59, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 13.9, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 11.14, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 25, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 348.06, "latest_week": "2026-06-19", "one_week_move": 9.5, "four_week_move": 16.2, "twelve_week_move": 41.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.908748, "market_dynamics_buy_signal": false, "relative_strength": 28.652262, "fair_value_gap": 96.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 49.5387, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+9.5% over one week, +16.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "simplywall.st", "count": 7}, {"label": "Simply Wall Street", "count": 5}, {"label": "TradingKey", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "Investing.com", "count": 2}, {"label": "DirectorsTalk Interviews", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Earnings", "count": 22}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+9.5% over one week, +16.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Krystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levels"}], "updated_at": "2026-06-23T02:18:48.173751+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}